The databook is designed to serve as a comprehensive guide to navigating this
sector. The databook focuses on market statistics denoted in the form of
revenue and y-o-y growth and CAGR across the globe and regions. A detailed
competitive and opportunity analyses related to investigational new drug cdmo market will
help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of
88.76% in
2021.
Horizon Databook has segmented the Middle East & Africa investigational new drug cdmo market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to
2028.
- Middle East & Africa Investigational New Drug CDMO Product Outlook (Revenue, USD Million, 2018-2028)
- Small Molecule
- Large Molecule
- Middle East & Africa Investigational New Drug CDMO Services Outlook (Revenue, USD Million, 2018-2028)
- Contract Development
- Small Molecule
- Bioanalysis and DMPK studies
- Toxicology Testing
- Pathology and safety pharmacology studies
- Drug substance synthetic route development
- Drug substance process development
- Form selection crystallization process development
- Scale-up of drug substance
- Preformulation
- Preclinical formulation selection
- First in Man Formulation/ Process Development
- Analytical method development / validation
- Release testing of drug substance and drug product
- Work up Purification Steps
- Telescoping & Process Refining
- Initial Optimization
- Formal stability of drug substance and drug product
- Large Molecule
- Cell Line development
- Process Development
- Upstream
- Downstream
- MABs
- Recombinant proteins
- Others
- Contract Manufacturing
- Small Molecule
- Oral Solids
- Liquid and Semi-solids
- Injectables
- Others
- Large Molecule
- MABs
- Recombinant proteins
- Others
- Middle East & Africa Investigational New Drug CDMO End Use Outlook (Revenue, USD Million, 2018-2028)
- Pharmaceutical Companies
- Biotech Companies
- Others
Reasons to
subscribe to Middle East & Africa investigational new drug cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of
Middle East & Africa investigational new drug cdmo market databook
-
Our clientele includes a mix of investigational new drug cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed
overview of
continent-level
data and insights on the Middle East & Africa investigational new drug cdmo market , including
forecasts for subscribers. This
continent
databook contains high-level insights into
Middle East & Africa investigational new drug cdmo market from
2018 to
2028, including revenue
numbers, major trends, and company profiles.